Clinical trials: Cyclophosphamide, completed
Advanced or Unresectable Melanoma Progressing After PD1 Blockade
A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade
This is a multi center, phase I pilot study of sequential ONCOS-102 and pembrolizumab in patients with advanced or unresectable melanoma progressing after PD1 blockade.
- Trial name
- NCT03003676
- Testing
- ONCOS-102, Cyclophosphamide, Pembrolizumab
- Where
- 4 sites in United States, Norway
- Volunteers
- 21 people
- Sponsor
- Targovax Oy
Childhood Acute Erythroleukemia (M6), Childhood Acute Megakaryocytic Leukemia (M7)
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Randomized phase III trial to compare the effectiveness of different chemotherapy regimens with or without bone marrow transplantation in treating children who have acute myelogenous leukemia or myelodysplastic syndrome.
- Conditions
- Childhood Acute Erythroleukemia (M6), Childhood Acute Megakaryocytic Leukemia (M7), Childhood Acute Monoblastic Leukemia (M5a), Childhood Acute Monocytic Leukemia (M5b)
- Trial name
- NCT00002798
- Testing
- asparaginase, daunorubicin hydrochloride, fludarabine phosphate
- Where
- United States
- Volunteers
- 880 people
- Sponsor
- National Cancer Institute (NCI)
Systemic Lupus Erythematosus
A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE)
The purpose of this study is to evaluate the efficacy, safety and tolerability of belimumab administered subcutaneously (SC) to adult subjects with Systemic Lupus Erythematosus (SLE).
- Trial name
- BLISS-SC (NCT01484496)
- Testing
- Belimumab 200 mg SC, Standard therapy
- Where
- 207 sites in United States, Argentina and 29 more
- Volunteers
- 839 people
- Sponsor
- Human Genome Sciences Inc., a GSK Company
Mesothelioma, Malignant
......SMARTEST Trial......
The SMARTEST trial is a phase II non-blinded randomized trial designed to evaluate the benefit of low dose cyclophosphamide in sequential combination with sub-ablative radiation (Arm A) versus sub-ablative radiation alone (Arm B)…
- Trial name
- NCT05380713
- Testing
- Cyclophosphamide, Tremelimumab, Durvalumab
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University Health Network, Toronto
Breast Cancer
Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Participants With HER2-Positive Breast Cancer
To evaluate the efficacy and safety of treatment with MYOCET® (doxorubicin hydrochloride) in combination with cyclophosphamide and trastuzumab, 4 cycles, followed by docetaxel plus trastuzumab, 4 cycles, in women with stage II or…
- Trial name
- NCT00712881
- Testing
- Liposomal doxorubicin hydrochloride, Cyclophosphamide, Trastuzumab
- Where
- 22 sites in Austria, Belgium and 4 more
- Volunteers
- 126 people
- Sponsor
- Cephalon, Inc.
Central Nervous System Lymphoma
Nordic Study in Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma
The purpose of the study is to test the efficacy and tolerability of a multiagent chemotherapy treatment regimen without radiotherapy in patients with newly diagnosed lymphoma in the brain.
- Trial name
- NCT01458730
- Testing
- Immunochemotherapy
- Where
- Denmark
- Volunteers
- 66 people
- Sponsor
- University of Aarhus
Leukemia
Chemotherapy in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Alternating treatment with more than one drug may kill more cancer cells.
- Trial name
- NCT00003829
- Testing
- cyclophosphamide, fludarabine phosphate
- Where
- 17 sites in United States
- Volunteers
- 34 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Lymphoma, Leukemia
Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies
The goal of this clinical research study is to see if low intensity chemotherapy given together with the new drug 90Y Zevalin, followed by a transplant of blood or marrow stem cells from a donor can increase the length of…
- Trial name
- NCT00048737
- Testing
- Zevalin Radioimmunotherapy, Rituximab, Fludarabine
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- M.D. Anderson Cancer Center
Non-Hodgkin Lymphoma
EMD 521873 in Advanced Solid Tumors, MTD Finding
Primary trial objective in this three arm trial is to assess the safety and tolerability of EMD 521873, and to determine whether the maximum tolerated dose (MTD) is reached with EMD 521873 doses of up to 1.5 mg/kg given alone or…
- Trial name
- NCT01032681
- Testing
- EMD 521873
- Where
- 5 sites in Germany, Switzerland
- Volunteers
- 66 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Waldenstrom's Macroglobulinaemia
Randomised Trial in Waldenstrom's Macroglobulinaemia
The purpose of this trial is to assess tolerability and efficacy of the Bortezomib, Cyclophosphamide and Rituximab combination as initial therapy for previously untreated patients with symptomatic Waldenstrom's macroglobulinaemia.
- Trial name
- R2W (NCT01592981)
- Testing
- Bortezomib, Cyclophosphamide, Rituximab
- Where
- 30 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- University College, London
To Compare the Effects of Mycophenolate Mofetil With Cyclophosphamide in Neplaese Lupus Nephritis Patients
Cyclophosphamide Versus Mycophenolate Mofetil in Lupus Nephritis
This was a prospective open label randomized control trial, which was conducted for a period of one and half year from January 2014 to June 2015.
- Trial name
- NCT03200002
- Testing
- Cyclophosphamide, Mycophenolate Mofetil
- Volunteers
- 49 people
- Sponsor
- Chitwan Medical College
Soft Tissue Sarcoma, Bone Sarcoma
Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas
Phase I-II, single-arm, non-randomized, open-label, multicenter, international clinical trial, with two stages. Stage one has two cohorts (soft tissue sarcoma and bone sarcoma) and stage two has eight cohorts (DDCS, EMC, VS, SFT…
- Trial name
- ImmunoSarc (NCT03277924)
- Testing
- Sunitinib 37.5 MG, Sunitinib 25 MG [Sutent], Nivolumab 100 MG/10 ML [Opdivo], Epirubicin
- Where
- 13 sites in Italy, Spain and 1 more
- Volunteers
- 197 people
- Sponsor
- Grupo Espanol de Investigacion en Sarcomas
MDS, Leukemias
Safety Study of Bone Marrow Transplant Using Mismatched Tissue Followed by Chemotherapy
The purpose of this study is to see if giving high dose chemotherapy and total body irradiation before and repeating high dose chemotherapy after a bone marrow transplant could reduce the incidence of graft rejection and disease…
- Conditions
- MDS, Leukemias, Lymphomas
- Trial name
- NCT00796562
- Testing
- Busulfan, Cyclophosphamide, Total body irradiation
- Where
- 2 sites in United States
- Volunteers
- 107 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Diffuse Large B-Cell Lymphoma
A Study Comparing SIBP-02 and Rituximab Combination With CHOP in Previously Untreated Subjects With CD20+ DLBCL
This is a randomised, double-blind, positive drug parallel controlled equivalence clinical trial initiated at about 30 sites in China.
- Trial name
- NCT04361279
- Testing
- SIBP-02, Rituximab
- Where
- China
- Volunteers
- 421 people
- Sponsor
- Shanghai Institute Of Biological Products
Lymphoma
Surgery Alone or With CYC VBL and PRED or CVP Alone in Stage IA or IIA Nodular Lymphocyte-Predominant Hodgkin Lymphoma
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, vinblastine, and prednisolone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- EuroNetLP1 (NCT01088750)
- Testing
- cyclophosphamide, prednisolone, vinblastine sulfate
- Where
- Germany
- Volunteers
- 225 people
- Sponsor
- Christine Mauz-Körholz
Lymphoma
Rituximab and Cyclophosphamide Followed by Vaccine Therapy in Treating Patients With Relapsed Hodgkin Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00134082
- Testing
- KGEL vaccine, Filgrastim, Rituximab
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Lymphoma
Chemotherapy and Whole-Brain Radiation Therapy in Treating Patients With Primary Central Nervous System Non- Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00002676
- Testing
- carmustine, cyclophosphamide, cytarabine
- Where
- 21 sites in United States
- Volunteers
- 36 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Lymphoma
Comparison Study of Doxorubicin Versus Epirubicin-induced Cardiotoxicity in Patients With DLBCL
The aim of this study is to compare CHOP versus CEOP-induced cardiotoxicity in patients with aggressive B-cell lymphoma. The hypothesis is epirubicin is associated with less cardiotoxicity without compromising the efficacy.
- Trial name
- NCT00854568
- Testing
- CEOP regimen, CHOP regimen
- Where
- China
- Volunteers
- 398 people
- Sponsor
- Fudan University
Mantle Cell Lymphoma
Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma
Patients will receive Rituximab, Bortezomib, cyclophosphamide, Doxorubicin, Vincristine, Dexamethasone in three week intervals for 6 cycles; then rituximab consolidation (weekly x 4) , then one dose of rituximab every 12 weeks…
- Trial name
- NCT00581776
- Testing
- Bortezomib, Rituximab, Cyclophosphamide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Wisconsin, Madison
CMV Infection
Cytomegalovirus Infection After HSCT and PT-CY as GVHD Prophylaxis >> GVHD PROPHYLAXIS ERA
Multicentre, observational, retrospective study to analyze the differences in CMVi pattern and recurrences between two groups of allogeneic HSCT patients (haplo vs no haplo HSCT), with intervention both postransplant…
- Trial name
- CY-CMV-2020 (NCT05315882)
- Where
- Spain
- Volunteers
- 300 people
- Sponsor
- Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.